Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorBilici, Ahmet
dc.contributor.authorOlmez, Omer Fatih
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorSezer, Ahmet
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorCubukcu, Erdem
dc.contributor.authorSendur, Mehmet Ali Nahit
dc.contributor.authorAksoy, Sercan
dc.contributor.authorErdem, Dilek
dc.contributor.authorBasaran, Gul
dc.contributor.authorCakar, Burcu
dc.contributor.authorShbair, Abdallah T. M.
dc.contributor.authorArslan, Cagatay
dc.contributor.authorSumbul, Ahmet Taner
dc.contributor.authorSezgin Goksu, Sema
dc.contributor.authorKaradag, Ibrahim
dc.contributor.authorCicin, Irfan
dc.contributor.authorGumus, Mahmut
dc.contributor.authorSelcukbiricik, Fatih
dc.contributor.authorHarputluoglu, Hakan
dc.contributor.authorDemirci, Umut
dc.date.accessioned2025-10-16T15:15:33Z
dc.date.issued2023
dc.identifier.doi10.1080/0284186X.2023.2202330
dc.identifier.otherWOS:000971681800001
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6477
dc.publisherMedical Journal Sweden AB
dc.sourceACTA ONCOLOGICA
dc.subjectHER2 protein positive
dc.subjectbreast cancer
dc.subjectneoadjuvant treatment
dc.subjectpertuzumab
dc.subjecttrastuzumab
dc.subjectevent\\-free survival
dc.subjectrelapse
dc.subjectreal\\-word evidence
dc.titleImpact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS